PT - JOURNAL ARTICLE AU - Lize M. Grobbelaar AU - Chantelle Venter AU - Mare Vlok AU - Malebogo Ngoepe AU - Gert Jacobus Laubscher AU - Petrus Johannes Lourens AU - Janami Steenkamp AU - Douglas B. Kell AU - Etheresia Pretorius TI - SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19 AID - 10.1101/2021.03.05.21252960 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.05.21252960 4099 - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252960.short 4100 - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21252960.full AB - Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-induced infection, the cause of coronavirus disease 2019 (COVID-19), is characterized by unprecedented clinical pathologies. One of the most important pathologies, is hypercoagulation and microclots in the lungs of patients. Here we study the effect of isolated SARS-CoV-2 spike protein S1 subunit as potential inflammagen sui generis. Using scanning electron and fluorescence microscopy as well as mass spectrometry, we investigate the potential of this inflammagen to interact with platelets and fibrin(ogen) directly to cause blood hypercoagulation. Using platelet poor plasma (PPP), we show that spike protein may interfere with blood flow. Mass spectrometry also showed that when spike protein S1 is added to healthy PPP, it results in structural changes to β and γ fibrin(ogen), complement 3, and prothrombin. These proteins were substantially resistant to trypsinization, in the presence of spike protein S1. Here we suggest that, in part, the presence of spike protein in circulation may contribute to the hypercoagulation in COVID-19 positive patients and may cause substantial impairment of fibrinolysis. Such lytic impairment may result in the persistent large microclots we have noted here and previously in plasma samples of COVID-19 patients. This observation may have important clinical relevance in the treatment of hypercoagulability in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNovo Nordisk Foundation for funding (grant NNF10CC1016517).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical clearance for the study was obtained from the Health Research Ethics Committee (HREC) of Stellenbosch University (South Africa) (reference: N19/03/043, project ID: 9521).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshttps://1drv.ms/u/s!AgoCOmY3bkKHisg5J0nb6wqsBzzWAQ?e=XAsc7w